Hims & Hers Health, Inc. (HIMS)
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Hims & Hers Expands Health Access Through Subscription Revenue Model
HIMS boosts predictable revenue and customer loyalty with a flexible, subscription-based model across key health categories.
Buy HIMS Stock At $56?
Hims & Hers stock (NASDAQ: HIMS) has recently witnessed a remarkable rebound, climbing 42% over the last month from approximately $42 to its current price of $59. This significant increase is primarily due to the announcement that a U.S. federal judge dismissed a lawsuit brought by Eli Lilly against a rival telehealth company, Willow Health, on September 2, 2025.
Hims & Hers Health, Inc. (HIMS) Laps the Stock Market: Here's Why
The latest trading day saw Hims & Hers Health, Inc. (HIMS) settling at $59.12, representing a +1.23% change from its previous close.
HIMS vs. DOCS: Which Digital Health Platform Is a Better Investment?
Hims & Hers and Doximity are transforming digital health, but which leads in earnings growth and platform expansion? Let's see.
Hims & Hers Health: Bumpy Ride Will End
Hims & Hers Health has traded very volatile over the last year as the market misunderstand the business opportunity beyond GLP-1s and weight-loss drugs. The online health and wellness faces FDA scrutiny, but this is industry-wide and not unique to the company. The platform is rapidly growing subscribers, launching new offerings, and targeting large under-penetrated markets domestically and internationally in a path to hitting a $6.5B 2030 sales target.
Hims & Hers Expands AI and Technology Focus to Advance Digital Care
HIMS boosts AI investment and appoints a new CTO as it advances personalized, technology-driven digital healthcare at scale.
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know
Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Hims & Hers: The Next Chapter For Investors
Revenue is scaling rapidly, from $150M in 2020 to ~$2.3B expected in 2025. Over 90% of revenue is recurring subscriptions, ensuring stability and visibility. The vertically integrated model builds a brand moat and delivers 76% gross margins.
Hims & Hers Health: At The Intersection Of Secular Megatrends
Hims & Hers Health, Inc. remains a Strong Buy as it is well-positioned to capitalize on secular wellness and digital health trends favored by younger generations. The company boasts stellar fundamentals, with 72.6% year-over-year revenue growth and strong EBITDA expansion, indicating robust profit potential. HIMS stock's valuation is attractive: forward P/E and P/S ratios suggest a 26% upside by the end of FY2026, supported by aggressive revenue and EPS growth forecasts.
Hims & Hers Health: Still Undervalued
Hims & Hers is fundamentally undervalued, trading at a forecast P/S ratio of 3.5 despite strong 88% YoY growth and European expansion. Low valuation and scaling by ZAVA lead to a buy rating. Short interest remains high, but a squeeze is unlikely; technicals show strong support at $41, signaling a favorable buy zone.
Hims & Hers: The Dominant Health Platform Of The Future
Hims & Hers is evolving into a robust health platform, showing strong subscriber growth, rising ARPU, and expanding into weight loss, hormone health, labs, and international markets. Q2 results confirm rapid scaling, with 73% YoY revenue growth, high retention, SaaS-like payback, and reaffirmed guidance despite headline noise and regulatory shifts. The weight loss strategy is diversified beyond compounded GLP-1s, supporting resilient ARPU and engagement, while international expansion and lab integration add new growth levers.
